Prakt. lékáren. 2015; 11(3): 93-95

Co-analgesics - the optimal choice and indication

PharmDr.Jitka Rychlíčková0,2
1 Oddělení klinické farmacie, Nemocnice Na Bulovce, Praha
2 Ústav aplikované farmacie, Farmaceutická fakulta VFU, Brno

Co-analgesics are a diverse group of drugs that includes anticonvulsants and antidepressants, and others (local anaesthetics, bisphosphonates,

calcitonin, muscle relaxants, corticosteroids, spasmolytics, benzodiazepines). They can be used at any step of the WHO ladder

alone or in combination with other analgesics.

Correct choice of co-analgesics is summarized in the following text. Determination of the pain etiology is the first step. Carbamazepin

appears to be effective in paroxysmal neuropathic pain, pregabalin and gabapentin are drugs of choice in painful polyneuropathy,

including diabetic neutopathic pain, tricyclic antidepressants can be used as well, but only as off label. In the second step, adverse drug

reaction, pharmacokinetics, potential drug interaction and patient´s age and comorbidities have to be considered.

Keywords: co-analgesics, neuropathic pain, indication, adverse drug reaction, pharmacokinetics

Published: May 25, 2015  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Rychlíčková J. Co-analgesics - the optimal choice and indication. Praktické lékárenství. 2015;11(3):93-95.
Download citation

References

  1. Doležal T. Metodické pokyny pro farmakoterapii bolesti. Doporučený postup České společnosti pro studium a léčbu bolesti [online]. Přepracované vydání. 2009. [cit. 2015-02-26]. Dostupný z WWW: <http://www.pain.cz/home.php>
  2. Attal N. EFNS guidelines on pharmacological treatment of neuropathic pain. European Journal of Neurology 2006; 13: 1153-1169. Go to original source... Go to PubMed...
  3. Bednařík J. Klinický standard pro farmakoterapii neuropatické bolesti, verze 1.0 [online]. 2011. [cit. 2015-02-26]. Dostupný z WWW: <www.czech-neuro.cz>
  4. Neuropathic pain - pharmacological management: The pharmacological management of neuropathic pain in adults in non-specialist settings. NICE guidelines [CG173] [online]. 2013-11-01 [cit. 2015-02-26]. Dostupný na WWW: <https://www.nice.org.uk/guidance/cg173>
  5. Bockbrader HN. A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. Clin Pharmacokinet 2010; 49(10): 661-669. Go to original source... Go to PubMed...
  6. Vondráčková D. Farmakoterapie neuropatické bolesti. Klinická farmakologie a farmacie 2009; 23(4): 181-186.
  7. Ambrósio AF. Mechanism of action of carbamazepine and its derivates, oxcarbazepin, BIA 2-093, and BIA 2-024. Neurochemical Research 2002; 27(1/2): 121-130. Go to original source... Go to PubMed...
  8. Dworkin RH. Pharmacologic management of neuropathic pain: Evidence-based recommendations. Pain 2007; 132: 237-251. Go to original source... Go to PubMed...
  9. Ashley C, Currie A. The renal drug handbook. New York: Radcliffe Publishing Ltd 2004: 794 s.
  10. Buschmann H, Christoph T, Friderichs E, Maul C, Sundermann B. Analgesics. From chemistry and pharmacology to clinical application. Weinheim: WILEY-VCH Verlag GmbH & Co. KGaA 2002: 604 s. Go to original source...
  11. Hegmonová E. Neuropatická bolest u onkologického pacienta. Onkologie 2012; 6(1): 12-17.
  12. Micro-verze AISLP. 2015.1 pro MS Windows. Databáze AISLP. [cit. 2015-02-27].




Pharmacy for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.